ZOSYN SUMMARY
Zosyn®
(Piperacillin and Tazobactam For Injection)
Amiodarone hydrochloride injection is a class III antiarrhythmic drug.
Amiodarone HCl injection is indicated for initiation of treatment and prophylaxis of frequently recurring ventricular fibrillation and hemodynamically unstable ventricular tachycardia in patients refractory to other therapy. Amiodarone injection also can be used to treat patients with VT/VF for whom oral amiodarone is indicated, but who are unable to take oral medication. During or after treatment with intravenous amiodarone injection patients may be transferred to oral amiodarone therapy (see DOSAGE AND ADMINISTRATION).
Amiodarone injection should be used for acute treatment until the patient's ventricular arrhythmias are stabilized. Most patients will require this therapy for 48 to 96 hours, but amiodarone injection may be safely administered for longer periods if necessary.
|
NEWS HIGHLIGHTS
Published Studies Related to Zosyn (Piperacillin / Tazobactam)
Piperacillin/tazobactam versus cefepime for the empirical treatment of pediatric cancer patients with neutropenia and fever: a randomized and open-label study. [2009.10]
OBJECTIVES: This is a prospective, randomized, and open-label clinical trial that examines the efficiency and safety of PIP/TAZO monotherapy in comparison to cefepime (CEF), for the empirical treatment of pediatric cancer patients with neutropenia and fever... CONCLUSIONS: PIP/TAZO treatment was as effective and safe as CEF monotherapy as an initial empirical regimen in pediatric cancer patients with fever and neutropenia.
Lack of pharmacokinetic drug interactions following concomitant administration of telavancin with aztreonam or piperacillin/tazobactam in healthy participants. [2009.07]
This randomized crossover study in healthy participants assessed pharmacokinetic interactions between telavancin, aztreonam, and piperacillin/tazobactam... Administration of aztreonam or piperacillin/tazobactam with telavancin had no clinically significant effect on the pharmacokinetic disposition of any of these drugs.
Piperacillin/tazobactam plus ceftazidime versus sulbactam/ampicillin plus aztreonam as empirical therapy for fever in severely neutropenic pediatric patients. [2009.04]
CONCLUSIONS: PIPC/TAZ+CAZ and SBT/ABPC+AZT are effective and safe for initial empirical treatment of febrile episodes in neutropenic pediatric patients. The clinical efficacy of SBT/ABPC+AZT is equivalent or superior to that of PIPC/TAZ+CAZ, the effect of which is already proven against febrile neutropenia. Therefore, SBT/ABPC+AZT may be a treatment of choice for febrile neutropenia in pediatric cancer patients.
A prospective, randomized study comparing cefozopran with piperacillin-tazobactam plus ceftazidime as empirical therapy for febrile neutropenia in children with hematological disorders. [2008.12]
CONCLUSION: Both cefozopran and PIPC/TAZ + CAZ combination therapy are safe and well tolerated in pediatric neutropenic patients. Our results show that cefozopran is a good candidate for monotherapy for neutropenic fever.
Pharmacoeconomics of Ciprofloxacin plus Metronidazole vs. Piperacillin-Tazobactam for Complicated Intra-Abdominal Infections. [2008.06]
ABSTRACT Background: A series of 459 hospitalized adults with complicated intra-abdominal infections participated in a randomized, double-blind, multicenter clinical trial. The present study was conducted to add a pharmacoeconomic analysis to the results... Lower costs were documented for patients able to be switched to oral antibiotics and for patients with appendicitis.
Clinical Trials Related to Zosyn (Piperacillin / Tazobactam)
Study Comparing Piperacillin-Tazobactam Versus Piperacillin-Tazobactam Plus Glycopeptide in Neutropenic Patients [Recruiting]
The aim of this study is to compare the efficacy and tolerance of piperacillin-tazobactam
versus piperacillin-tazobactam plus glycopeptide as initial empiric antibiotic treatment for
fever in neutropenic patients. Study of consecutive cohorts(2). First the patients will
be included in the monotherapy branch until completing the predicted number of cases. When
this happens, the Coordinating Center will communicate it to the participant centers and
from then the patients will be included in the combined therapy.
Pharmacokinetics and Safety of Piperacillin-Tazobactam in Neonates [Not yet recruiting]
This is a phase I open label multi-dose study to investigate the pharmacokinetics and safety
of piperacillin-tazobactam in infants < 61 days of age with suspected sepsis. There will be
four cohorts of 8 infants each:
1. < 32 weeks gestational age and < 14 days postnatal age
2. < 32 weeks gestational age and >=14 days postnatatal age
3. >=32 weeks gestational age and < 14 days postnatal age
4. >=32 weeks gestational age and >=14 days postnatal age. The study requires
administration of 6 doses of study drug along with other antimicrobials per standard of
care followed by 1 week of safety monitoring. Four 200 µL pK samples will be obtained
at steady state. The risks are reasonable vs. the benefits and have been minimized
appropriately. There may be benefit to the subjects (administration of broad spectrum
empirical antimicrobial therapy), and information from the study may benefit a large
number of other infants in whom the drug is currently being administered despite the
lack of PK data in this population.
Study Evaluating Zosyn in Hospitalized Patients With Intra-Abdominal Infection [Completed]
A Phase IV, multicenter study of hospitalized patients with complicated intra-abdominal
infection.
Study Evaluating Piperacillin-Tazobactam on Certain Bacteria in Hematology and Oncology Units [Completed]
Tazocin Intervention Study [Completed]
|
